ClinicalTrials.gg
CompletedNCT02592798Updated Mar 5, 2021Results posted

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

A Phase 2 interventional study of Abatacept and Normal Saline in Nephrotic Syndrome, Focal Segmental Glomerulosclerosis and Minimal Change Disease, sponsored by Bristol-Myers Squibb. Completed at 27 sites in United States. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2021-03-05.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
6 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies in Nephrotic Syndrome with a site in United States — 12 open to participants now, 13 under way, none of them phase 3. Nephrotic Syndrome · United States.

Enrollment
12th of 38
36 · median 26
Started
2016
with 1 other
Phase 2
18 of 51
4 open now
Registered
29th of 51
by date

Among the 51 studies in Nephrotic Syndrome with a site in United States, this one is the 12th largest by enrollment of the 38 interventional ones that give a count, is one of 2 that started in 2016, is one of 18 in phase 2, and was the 29th registered.

Nephrotic Syndrome

192 studies on the registry are indexed under Nephrotic Syndrome; 65 are open to participants now.

Browse Nephrotic Syndrome studies →

Open to participants now

12 of the 51 studies in Nephrotic Syndrome with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Nephrotic Syndrome studies recruiting now, 23 (46%) set no upper age limit and 22 (44%) stop at 75 or younger; 37 take children under 18; 4 take healthy volunteers.

This study: 6 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Nephrotic Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is evaluate if abatacept is effective and safe in decreasing the level of protein loss in the urine in patients with excessive loss of protein in the urine (nephrotic syndrome) due to either focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD). Candidates must have a prior kidney biopsy with either diagnosis. Another kidney biopsy will not be required as part of the study. Candidates must have failed or be intolerant of prior therapy for their kidney disease. The failed or intolerant therapy must include corticosteroids and at least one other drug. Candidates can be adults and children over the age of 6. Abatacept will be administered by venous infusion every 4 weeks.

03

Conditions studied

  • Nephrotic Syndrome
  • Focal Segmental Glomerulosclerosis
  • Minimal Change Disease
04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Male and female subjects ages ≥ 6 years
  • Subjects resistant to , calcineurin inhibitors (cyclosporine and tacrolimus), sirolimus, mycophenolate mofetil (MMF), mycophenolic acid (MPA), or cyclophosphamide or intolerant to at least 2 of these
  • UPCR ≥ 3 at screening
  • FSGS or MCD confirmed by renal
  • ≥ 45 for children and adults
  • Concomitant use of angiotensin-converting-enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) at stable doses for at least 2 weeks or have intolerance documented in the source documents maintained at the site

Exclusion criteria

Exclusion Criteria:

  • Kidney diseases other than FSGS or MCD
  • Collapsing FSGS
  • Systemic lupus erythematosus
  • Diabetes mellitus, both type 1 and type 2
  • congestive heart failure
  • Post renal transplantation, including relapsing post-transplant FSGS
  • (BMI): > 40 in subjects ≥ 18 years of age and ≥ 99% percentile for subjects \< 18 years of age

Other protocol defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Abatacept

    * Double Blind Periods 1 and 2 (DB1 and DB2): Abatacept IV administered on Day 1, 15, 29 and then every 28 days until the end of the Double Blind Period. * Open Label Period (OLE): Abatacept IV administered every 28 days

    Drug: Abatacept

  • Placebo comparator
    Placebo

    * Double Blind Periods 1 and 2 (DB1 and DB2): Normal Saline or Dextrose 5% in Water (D5W) administer on Day 1, 15, 29 and then every 28 days until the end of the Double Blind Period. * Open Label Period (OLE): Abatacept IV administered every 28 days

    Other: Normal Saline · Other: D5W

Interventions

  • Abatacept IV administered on Day 1, 15, 29 and then every 28 days

  • OtherNormal Saline

    Normal Saline administer on Day 1, 15, 29 and then every 28 days

  • OtherD5W

    Dextrose 5% in Water (D5W) administered on Day 1, 15, 29 and then every 28 days

    Also known as: 5% Dextrose in Water

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in Renal Response at Day 113

    Renal Response is defined as the presence of all the following criteria: PROTEINURIA: Reduction of baseline urine protein/creatinine ratio (UPCR) of \>= 50% and to less than 3. RENAL FUNCTION: No worsening of baseline estimated glomerular filtration rate (eGFR) defined as within normal range if normal at baseline or ≥ 75% baseline value if below normal at baseline.

    Time frame: From first dose to 113 days following first dose of the indicated period (113 days for Double-Blind Period, 226 days for Open Label Period)

Secondary outcomes

  1. Mean Change From Baseline in Urine Protein/Creatinine Ratio (UPCR) at Day 113

    Time frame: From baseline (measured at day 1 of study) to 113 days following first dose administered in the indicated treatment period (113 days for Double-Blind Period, 226 days for Open Label Period)

  2. Mean Change From Baseline in Serum Albumine at Day 113

    Time frame: From baseline (measured at day 1 of the study) to 113 days following first dose administered in the indicated treatment period (113 days for Double-Blind Period, 226 days for Open Label Period)

  3. Percentage of Participants Achieving Complete Remission at Day 113

    Complete Remission is defined as the presence of all the following criteria: PROTEINURIA: Urine protein/creatinine ratio (UPCR) ≤ 0.3. RENAL FUNCTION: No worsening of baseline estimated glomerular filtration rate (eGFR) defined as within normal range if normal at baseline or ≥ 75% baseline value if below normal at baseline.

    Time frame: From first dose to 113 days following first dose of the indicated period (113 days for Double-Blind Period, 226 days for Open Label Period)

  4. Mean Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) at Day 113 - Adult Participants

    PROMIS was used to capture patient reported outcomes relevant to participants with nephrotic syndrome. Mean change from baseline is reported for the following measurements: Fatigue: Short From (SF) Fatigue v1.0 Adult 8a, composed of 8 questions, each one scored from 1 (Not at all) to 5 (Very much). Output presented as Total score, ranging from 8 (most desirable outcome) to 40 (least desirable outcome). Pain Interference: SF Pain Interference v1.0 Adult 8a, (measuring how much pain is interfering with daily activities). Composed of 8 questions, each one scored from 1 (Not at all) to 5 (Very much). Output presented as Total score, ranging from 8 (most desirable outcome) to 40 (least desirable outcome). Physical Function: SF Physical Function v1.2 Adult 8b, composed of 8 questions, each one scored from 1 (Without any difficulty) to 5 (Unable to do). Output presented as Total score, ranging from 8 (most desirable outcome) to 40 (least desirable outcome).

    Time frame: From baseline (measured at day 1 of study) to 113 days following first dose administered in the Double-Blind Period

  5. Mean Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) at Day 113 - Pediatric Participants

    PROMIS was used to capture patient reported outcomes relevant to participants with nephrotic syndrome. Mean change from baseline is reported for the following measurements: Fatigue: Short From (SF) Fatigue v1.0 Peds 10a, composed of 10 questions, each one scored from 0 (Never) to 4 (Almost Always). Output presented as Total score, ranging from 0 (most desirable outcome) to 40 (least desirable outcome). Pain Interference: SF Pain Interference v1.0 Peds 8a, ( measuring how much pain is interfering with daily activities). Composed of 8 questions, each one scored from 0 (Never) to 4 (Almost always). Output presented as Total score, ranging from 0 (most desirable outcome) to 32 (least desirable outcome). Mobility: SF Physical Function-Mobility v1.0 Peds 8a, composed of 8 questions, each one scored from 0 (Not able to do) to 4 (With no trouble). Output presented as Total score, ranging from 0 (least desirable outcome) to 32 (most desirable outcome).

    Time frame: From baseline (measured at day 1 of study) to 113 days following first dose administered in the Double-Blind Period

  6. Number of Participants Experiencing Adverse Events

    This outcome describes the number of participants experiencing various types of any grade Adverse Events (AEs). The Cumulative Abatacept Safety Period starts at the time of the first dose of Abatacept (either in the Double-Blind Period or in the Open Label Period) and lasts 56 days after the last dose of Abatacept

    Time frame: From first dose in the indicated period to 56 days following last dose in the indicated period (169 days for the Double-Blind Period, up to 337 days for the Cumulative Abatacept Safety Period)

  7. Number of Participants Experiencing Adverse Events of Special Interest

    Number of participants experiencing various types of Adverse Events of interest, including infections, malignancies, autoimmune disorders, and infusional related reactions.

    Time frame: From first dose on day 1 to 56 days following last dose (approximately 330 days)

  8. Percentage of Participants With Positive Antibody Response Relative to Baseline

    A positive response relative to baseline is defined as a positive response at a post-baseline visit that has a titer value greater than the positive baseline titer value. If the baseline titer is missing or negative, any post-baseline positive titer value is considered a positive response relative to baseline. Immunogenicity response is presented as the total of immunogenicity response for "CTLA4 and possibly Ig" and "Ig and/or Junction Region".

    Time frame: From baseline (day 1) to 168 days following last dose (up to 15 months). Results at day 113 from first dose, day 56, day 84 and day 168 after last dose are presented

  9. Minimum Blood Plasma Concentration (Cmin) of Abatacept - Adult Participants

    Time frame: From first dose to 113 days after first dose in the Double Blind Period. Data collected on day 15, day 29, day 57, day 85 and day 113

  10. Minimum Blood Plasma Concentration (Cmin) of Abatacept - Pediatric Participants

    Time frame: From first dose to 113 days after first dose in the Double Blind Period. Data collected on day 15, day 29, day 57, day 85 and day 113

  11. Maximum Observed Serum Concentration (Cmax) of Abatacept

    Time frame: Day 85 after first dose in the Double Blind Period

  12. Area Under the Serum Concentration Time Curve Over a Dosing Interval (AUC(TAU)) of Abatacept

    Time frame: From Day 85 to Day 113 in the Double Blind Period

  13. Time to Reach Peak Serum Concentration (Tmax(h)) of Abatacept

    Time frame: Day 85 after first dose in the Double Blind Period

07

Results

Posted Mar 5, 2021
Limitations and caveats
Amendment 02 of the Clinical Protocol (18 April 2018) modified the study design, so that the Double-Blind Period (DB) would not include anymore 2 consecutive periods (DB1 and DB2). However, for transparency and completeness reasons, in the Participant Flow and Adverse Events sections data about DB1 and DB2 are reported separately.

Participant flow

Double-Blind Period 1 (DB1)
Participant flow — Double-Blind Period 1 (DB1)
MilestoneAbataceptPlacebo
Started1719
Completed1413
Not completed36
Withdrew: Pregnancy10
Withdrew: No longer meeting study criteria01
Withdrew: Lack of efficacy13
Withdrew: Adverse event12
Transition From DB1 to DB2
Participant flow — Transition From DB1 to DB2
MilestoneAbataceptPlacebo
Started1413
Completed1111
Not completed32
Withdrew: Skipped db2 and moved into subsequent ole32
Double-Blind Period 2 (DB2)
Participant flow — Double-Blind Period 2 (DB2)
MilestoneAbataceptPlacebo
Started1111
Completed69
Not completed52
Withdrew: Other reasons10
Withdrew: Participant request to discontinue10
Withdrew: No longer meeting study criteria10
Withdrew: Lack of efficacy12
Withdrew: Adverse event10
Transition From DB2 to OLE
Participant flow — Transition From DB2 to OLE
MilestoneAbataceptPlacebo
Started69
Completed59
Not completed10
Withdrew: Other reasons10
Open Label Period (OLE)
Participant flow — Open Label Period (OLE)
MilestoneAbataceptPlacebo
Started1013
Completed64
Not completed49
Withdrew: Other reasons02
Withdrew: Participant request to discontinue10
Withdrew: Lost to follow-up01
Withdrew: Lack of efficacy35
Withdrew: Adverse event01

Outcome measures

PrimaryPercentage of Participants in Renal Response at Day 113

Renal Response is defined as the presence of all the following criteria: PROTEINURIA: Reduction of baseline urine protein/creatinine ratio (UPCR) of \>= 50% and to less than 3. RENAL FUNCTION: No worsening of baseline estimated glomerular filtration rate (eGFR) defined as within normal range if normal at baseline or ≥ 75% baseline value if below normal at baseline.

Time frame:
From first dose to 113 days following first dose of the indicated period (113 days for Double-Blind Period, 226 days for Open Label Period)
Reported as:
Number · Percent of Participants
Percentage of Participants in Renal Response at Day 113
Percent of ParticipantsAbataceptPlacebo
Double-Blind Period Day 1130.0 (0.0 to 24.7)7.7 (0.2 to 36.0)
Open Label Period Day 11312.5 (0.3 to 52.7)33.3 (7.5 to 70.1)
Statistical analysis
  • Abatacept vs Placebo · Mean difference (final values): -7.7 · 95% CI -46.8 to 33.3Abatacept - Placebo for Double-Blind Period Day 113
  • Abatacept vs Placebo · Mean difference (final values): -20.8 · 95% CI -63.3 to 24.3Abatacept - Placebo for Open Label Period Day 113
SecondaryMean Change From Baseline in Urine Protein/Creatinine Ratio (UPCR) at Day 113
Time frame:
From baseline (measured at day 1 of study) to 113 days following first dose administered in the indicated treatment period (113 days for Double-Blind Period, 226 days for Open Label Period)
Reported as:
Mean · mg/mg
Mean Change From Baseline in Urine Protein/Creatinine Ratio (UPCR) at Day 113
mg/mgAbataceptPlacebo
Double-Blind Period Day 1130.12 ± 0.5738-0.25 ± 0.7914
Open Label Period Day 1131.98 ± 1.15980.02 ± 1.3049
Statistical analysis
  • Abatacept vs Placebo · Mean difference (final values): 0.37 · 95% CI -1.6495 to 2.3855Abatacept - Placebo for Double-Blind Period Day 113
  • Abatacept vs Placebo · Mean difference (final values): 1.95 · 95% CI -1.7933 to 5.6954Abatacept - Placebo for Open Label Period Day 113
SecondaryMean Change From Baseline in Serum Albumine at Day 113
Time frame:
From baseline (measured at day 1 of the study) to 113 days following first dose administered in the indicated treatment period (113 days for Double-Blind Period, 226 days for Open Label Period)
Reported as:
Mean · g/dL
Mean Change From Baseline in Serum Albumine at Day 113
g/dLAbataceptPlacebo
Double-Blind Period Day 1130.08 ± 0.1016-0.05 ± 0.0892
Open Label Period Day 1130.21 ± 0.18290.09 ± 0.2360
Statistical analysis
  • Abatacept vs Placebo · Mean difference (final values): 0.13 · 95% CI -0.1483 to 0.4119Abatacept - Placebo for Double-Blind Period Day 113
  • Abatacept vs Placebo · Mean difference (final values): 0.12 · 95% CI -0.5107 to 0.7551Abatacept - Placebo for Open Label Period Day 113
SecondaryPercentage of Participants Achieving Complete Remission at Day 113

Complete Remission is defined as the presence of all the following criteria: PROTEINURIA: Urine protein/creatinine ratio (UPCR) ≤ 0.3. RENAL FUNCTION: No worsening of baseline estimated glomerular filtration rate (eGFR) defined as within normal range if normal at baseline or ≥ 75% baseline value if below normal at baseline.

Time frame:
From first dose to 113 days following first dose of the indicated period (113 days for Double-Blind Period, 226 days for Open Label Period)
Reported as:
Number · Percent of Participants
Percentage of Participants Achieving Complete Remission at Day 113
Percent of ParticipantsAbataceptPlacebo
Double-Blind Period Day 1130.0 (0.0 to 24.7)0.0 (0.0 to 24.7)
Open Label Period Day 11312.5 (0.3 to 52.7)11.1 (0.3 to 48.2)
Statistical analysis
  • Abatacept vs Placebo · Mean difference (final values): 1.4 · 95% CI -44.7 to 44.7Abatacept - Placebo for Open Label Period Day 113
SecondaryMean Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) at Day 113 - Adult Participants

PROMIS was used to capture patient reported outcomes relevant to participants with nephrotic syndrome. Mean change from baseline is reported for the following measurements: Fatigue: Short From (SF) Fatigue v1.0 Adult 8a, composed of 8 questions, each one scored from 1 (Not at all) to 5 (Very much). Output presented as Total score, ranging from 8 (most desirable outcome) to 40 (least desirable outcome). Pain Interference: SF Pain Interference v1.0 Adult 8a, (measuring how much pain is interfering with daily activities). Composed of 8 questions, each one scored from 1 (Not at all) to 5 (Very much). Output presented as Total score, ranging from 8 (most desirable outcome) to 40 (least desirable outcome). Physical Function: SF Physical Function v1.2 Adult 8b, composed of 8 questions, each one scored from 1 (Without any difficulty) to 5 (Unable to do). Output presented as Total score, ranging from 8 (most desirable outcome) to 40 (least desirable outcome).

Time frame:
From baseline (measured at day 1 of study) to 113 days following first dose administered in the Double-Blind Period
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) at Day 113 - Adult Participants
Score on a scaleAbataceptPlacebo
Fatigue-5.56 ± 2.2907-4.87 ± 2.6125
Pain Interference-4.88 ± 2.6395-1.18 ± 3.9785
Physical Function0.78 ± 1.73501.77 ± 1.9346
Statistical analysis
  • Abatacept vs Placebo · Mean difference (final values): -0.69 · 95% CI -8.1395 to 6.7645Abatacept - Placebo for Fatigue
  • Abatacept vs Placebo · Mean difference (final values): -3.70 · 95% CI -13.9402 to 6.5402Abatacept - Placebo for Pain interference
  • Abatacept vs Placebo · Mean difference (final values): -1.00 · 95% CI -6.5736 to 4.5736Abatacept - Placebo for Physical function
SecondaryMean Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) at Day 113 - Pediatric Participants

PROMIS was used to capture patient reported outcomes relevant to participants with nephrotic syndrome. Mean change from baseline is reported for the following measurements: Fatigue: Short From (SF) Fatigue v1.0 Peds 10a, composed of 10 questions, each one scored from 0 (Never) to 4 (Almost Always). Output presented as Total score, ranging from 0 (most desirable outcome) to 40 (least desirable outcome). Pain Interference: SF Pain Interference v1.0 Peds 8a, ( measuring how much pain is interfering with daily activities). Composed of 8 questions, each one scored from 0 (Never) to 4 (Almost always). Output presented as Total score, ranging from 0 (most desirable outcome) to 32 (least desirable outcome). Mobility: SF Physical Function-Mobility v1.0 Peds 8a, composed of 8 questions, each one scored from 0 (Not able to do) to 4 (With no trouble). Output presented as Total score, ranging from 0 (least desirable outcome) to 32 (most desirable outcome).

Time frame:
From baseline (measured at day 1 of study) to 113 days following first dose administered in the Double-Blind Period
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) at Day 113 - Pediatric Participants
Score on a scaleAbataceptPlacebo
Fatigue6.43 ± 6.7142-6.02 ± 3.6526
Pain Interference5.70 ± 3.9781-1.44 ± 1.9180
Mobility0.80 ± 3.50071.68 ± 3.1905
Statistical analysis
  • Abatacept vs Placebo · Mean difference (final values): 12.45 · 95% CI -4.5950 to 29.4850Abatacept - Placebo for Fatigue
  • Abatacept vs Placebo · Mean difference (final values): 7.14 · 95% CI -2.5917 to 16.8717Abatacept - Placebo for Pain interference
  • Abatacept vs Placebo · Mean difference (final values): -0.88 · 95% CI -12.1068 to 10.3468Abatacept - Placebo for Mobility
SecondaryNumber of Participants Experiencing Adverse Events

This outcome describes the number of participants experiencing various types of any grade Adverse Events (AEs). The Cumulative Abatacept Safety Period starts at the time of the first dose of Abatacept (either in the Double-Blind Period or in the Open Label Period) and lasts 56 days after the last dose of Abatacept

Time frame:
From first dose in the indicated period to 56 days following last dose in the indicated period (169 days for the Double-Blind Period, up to 337 days for the Cumulative Abatacept Safety Period)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events
ParticipantsAbatacept During Double-Blind PeriodPlacebo During Double-Blind PeriodAbatacept During Cumulative Abatacept Safety Period
Adverse Events (AEs)131526
Serious Adverse Events (SAEs)5410
AEs leading to discontinuation122
Deaths000
SecondaryNumber of Participants Experiencing Adverse Events of Special Interest

Number of participants experiencing various types of Adverse Events of interest, including infections, malignancies, autoimmune disorders, and infusional related reactions.

Time frame:
From first dose on day 1 to 56 days following last dose (approximately 330 days)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events of Special Interest
ParticipantsAbataceptPlacebo
Peri-infusional Adverse Event (AE)63
AE within 24 hours of Infusion89
Malignancies00
Infections/Infestations1210
Autoimmune disorders01
SecondaryPercentage of Participants With Positive Antibody Response Relative to Baseline

A positive response relative to baseline is defined as a positive response at a post-baseline visit that has a titer value greater than the positive baseline titer value. If the baseline titer is missing or negative, any post-baseline positive titer value is considered a positive response relative to baseline. Immunogenicity response is presented as the total of immunogenicity response for "CTLA4 and possibly Ig" and "Ig and/or Junction Region".

Time frame:
From baseline (day 1) to 168 days following last dose (up to 15 months). Results at day 113 from first dose, day 56, day 84 and day 168 after last dose are presented
Reported as:
Number · Percent of Participants
Percentage of Participants With Positive Antibody Response Relative to Baseline
Percent of ParticipantsAbataceptPlacebo
Day 113 from first dose7.10.0
Day 56 from last dose40.066.7
Day 84 from last dose28.666.7
Day 168 from last dose16.725.0
SecondaryMinimum Blood Plasma Concentration (Cmin) of Abatacept - Adult Participants
Time frame:
From first dose to 113 days after first dose in the Double Blind Period. Data collected on day 15, day 29, day 57, day 85 and day 113
Reported as:
Geometric mean · ug/mL
Minimum Blood Plasma Concentration (Cmin) of Abatacept - Adult Participants
ug/mLAbataceptPlacebo
Day 157.613 ± 63.7—
Day 2912.274 ± 86.7—
Day 573.641 ± 66.5—
Day 854.101 ± 52.7—
Day 1132.786 ± 68.2—
SecondaryMinimum Blood Plasma Concentration (Cmin) of Abatacept - Pediatric Participants
Time frame:
From first dose to 113 days after first dose in the Double Blind Period. Data collected on day 15, day 29, day 57, day 85 and day 113
Reported as:
Geometric mean · ug/mL
Minimum Blood Plasma Concentration (Cmin) of Abatacept - Pediatric Participants
ug/mLAbataceptPlacebo
Day 152.829 ± 116.4—
Day 292.588 ± 138.7—
Day 570.504 ± 143.2—
Day 851.617 ± 123.5—
Day 1130.990 ± 163.1—
SecondaryMaximum Observed Serum Concentration (Cmax) of Abatacept
Time frame:
Day 85 after first dose in the Double Blind Period
Reported as:
Geometric mean · ug/mL
Maximum Observed Serum Concentration (Cmax) of Abatacept
ug/mLAbataceptPlacebo
Adult participants200.46 ± 43.9—
Pediatric participants174.65 ± 30.0—
SecondaryArea Under the Serum Concentration Time Curve Over a Dosing Interval (AUC(TAU)) of Abatacept
Time frame:
From Day 85 to Day 113 in the Double Blind Period
Reported as:
Geometric mean · ug*h/mL
Area Under the Serum Concentration Time Curve Over a Dosing Interval (AUC(TAU)) of Abatacept
ug*h/mLAbataceptPlacebo
Adult participants20394.83 ± 44.3—
Pediatric participants18282.50 ± 41.9—
SecondaryTime to Reach Peak Serum Concentration (Tmax(h)) of Abatacept
Time frame:
Day 85 after first dose in the Double Blind Period
Reported as:
Mean · Hours
Time to Reach Peak Serum Concentration (Tmax(h)) of Abatacept
HoursAbataceptPlacebo
Adult participants0.883 ± 0.242—
Pediatric participants0.589 ± 0.285—

Adverse events

Collected over From first dose to 100 days following administration of last dose (approximately 1 year). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abatacept During Double-Blind Period 1 (DB1)0/17 (0%)5/17 (29.4%)13/17 (76.5%)
Placebo During Double-Blind Period 1 (DB1)0/19 (0%)4/19 (21.1%)15/19 (78.9%)
Abatacept During Double-Blind Period 2 (DB2)0/11 (0%)0/11 (0%)7/11 (63.6%)
Placebo During Double-Blind Period 2 (DB2)0/11 (0%)2/11 (18.2%)8/11 (72.7%)
Abatacept During Open Label Period (OLE)0/23 (0%)6/23 (26.1%)16/23 (69.6%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventAbatacept During Double-Blind Period 1 (DB1)Placebo During Double-Blind Period 1 (DB1)Abatacept During Double-Blind Period 2 (DB2)Placebo During Double-Blind Period 2 (DB2)Abatacept During Open Label Period (OLE)
Generalised oedemaGeneral disorders2/170/190/110/111/23
OedemaGeneral disorders2/170/190/110/110/23
Acute kidney injuryRenal and urinary disorders0/172/190/111/111/23
AnaemiaBlood and lymphatic system disorders1/170/190/111/110/23
Thrombotic microangiopathyBlood and lymphatic system disorders0/170/190/111/110/23
Pneumonia respiratory syncytial viralInfections and infestations0/170/190/111/110/23
Renal failureRenal and urinary disorders0/170/190/111/111/23
Blood creatinine increasedInvestigations0/170/190/110/112/23
Chest painGeneral disorders1/170/190/110/110/23
Fluid overloadMetabolism and nutrition disorders1/170/190/110/110/23
Most frequent other events
Showing 10 of 103
Most frequent other events
EventAbatacept During Double-Blind Period 1 (DB1)Placebo During Double-Blind Period 1 (DB1)Abatacept During Double-Blind Period 2 (DB2)Placebo During Double-Blind Period 2 (DB2)Abatacept During Open Label Period (OLE)
VomitingGastrointestinal disorders5/172/190/110/113/23
HeadacheNervous system disorders2/175/191/112/112/23
DiarrhoeaGastrointestinal disorders4/173/190/111/113/23
OedemaGeneral disorders4/172/190/110/110/23
Pain in extremityMusculoskeletal and connective tissue disorders0/170/190/112/110/23
DizzinessNervous system disorders3/170/190/110/110/23
NauseaGastrointestinal disorders2/172/191/111/114/23
PyrexiaGeneral disorders1/172/190/110/114/23
Upper respiratory tract infectionInfections and infestations0/171/191/111/114/23
Nasal congestionRespiratory, thoracic and mediastinal disorders0/170/190/110/114/23

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AbataceptPlaceboTotal
Mean22.5 ± 13.2128.7 ± 19.3525.8 ± 16.80
Sex: Female, Male
Sex: Female, Male(Participants)AbataceptPlaceboTotal
Female81220
Male9716
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AbataceptPlaceboTotal
Hispanic or Latino257
Not Hispanic or Latino151429
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AbataceptPlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American437
White131427
More than one race000
Unknown or Not Reported022
08

Study locations

27 sites
  • The University Of Alabama At Birmingham
    Birmingham, Alabama 35233, United States
  • University of Alabama-Birmingham-Parent Account
    Birmingham, Alabama 35294, United States
  • Los Angeles Biomedical Research Institute
    Torrance, California 90502, United States
  • University Of Colorado Denver
    Aurora, Colorado 80045, United States
  • Children's National Health System
    Washington, District of Columbia 20010, United States
  • University Of Miami Miller School Of Medicine
    Miami, Florida 33136, United States
  • Nemours Childrens Hospital
    Orlando, Florida 32827, United States
  • Emory University
    Atlanta, Georgia 30322-1015, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • NIH Clinical Center - NIDDK
    Bethesda, Maryland 20892, United States
  • Boston Childrens Hospital
    Boston, Massachusetts 02115, United States
  • Brigham And Women'S Hosp Inc.
    Boston, Massachusetts 02115, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Childrens Mercy Hospital
    Kansas City, Missouri 64108, United States
  • New York University Langone Medical Center
    New York, New York 10016, United States
  • Columbia University Medical Center (Cumc)
    New York, New York 10032, United States
  • Levine Children's Hospital
    Charlotte, North Carolina 28203, United States
  • Duke University
    Durham, North Carolina 27701, United States
  • Cincinnati Children'S Hospital Medical Center
    Cincinnati, Ohio 45229-3039, United States
  • The Metro Health System
    Cleveland, Ohio 44109, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • University Of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Local Institution
    Pittsburgh, Pennsylvania 15224, United States
  • Renal Disease Research Institute
    Dallas, Texas 75235, United States
  • University Of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
09

References and documents

Publications

  • Azukaitis K, Palmer SC, Strippoli GF, Hodson EM. Interventions for minimal change disease in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2022 Mar 1;3(3):CD001537. doi: 10.1002/14651858.CD001537.pub5. PubMed 35230699 ↗
  • Hodson EM, Sinha A, Cooper TE. Interventions for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD003233. doi: 10.1002/14651858.CD003233.pub3. PubMed 35224732 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in Jan 2020, 46 months.

Results were first posted in Mar 2021, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2015
First posted
Oct 30, 2015
StartActual
Mar 9, 2016
Primary completionActual
Jan 28, 2020
CompletionActual
Jan 28, 2020
Results first posted
Mar 5, 2021
Last update
Mar 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02592798
Responsible party
Sponsor
First posted
Oct 30, 2015
Start date
Mar 9, 2016
Primary completion
Jan 28, 2020
Completion
Jan 28, 2020
Results posted
Mar 5, 2021
Last update
Mar 5, 2021

Study contacts

Bristol Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion